ADDRESSING CHALLENGES IN ORAL THERAPIES FOR HR+, HER2- BREAST CANCER

A diagnosis of hormone receptor-positive (HR+) breast cancer indicates that estrogen and/or progesterone hormone receptors are found in the cancer cells.1 If the breast cancer cells have a normal amount of HER2 on their surface, the cancer cells are called HER2 negative (HER2-).1,2 An HR+, HER2- diagnosis can require a complex treatment regimen tailored to an individual patient, that may include hormone therapy, chemotherapy or a combination of these.3 HR+, HER2- breast cancer is the most common subtype of breast cancer, accounting for about 70% of breast cancer cases.4,5

The complex and evolving treatment landscape for locally advanced or metastatic HR+, HER2-breast cancer poses a challenge to community oncologists, who are tasked with ensuring the tolerability and adherence of patients to their treatment regimens. Difficult dosing schedules and side effect profiles of oral anti-cancer therapies require working knowledge of a rapidly growing body of medical literature.